Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD)
Summary
The study is designed to identify the best outcome measures in assessing their suitability and the adaptability across a variety of countries and languages for future international clinical
trials for patients with CDD.
Eligibility
Eligible ages: 0 to 17
Inclusion criteria:
Patients ages newborn to 17 years old with documented diagnosis of CDKL5 deficiency
Exclusion criteria:
Any condition that, in the opinion of the investigator, would put the patient at
undue risk or make it unsafe for the patient to participate
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Dr. Julia Jacobs-LeVan at 4039552480 or Julia.Jacobs-LeVan@albertahealthservices.ca
Principal investigator:
Julia Jacobs-Levan
Clinical trial:
Yes
REB-ID:
REB22-0797